Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-255 Monotherapy or with Cetuximab in Solid Tumors
NCT04616196Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2020
- Primary completion
- Mar 2023
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of NKTR-255 in head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), sponsored by Nektar Therapeutics. Started Oct 2020; status: completed.
02
Drugs
NKTR-255
03
Conditions
head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04616196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616196.